This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Biohaven's BHV-1400, a next generation TRAP degrader, achieved rapi­d, deep, and selective lowering of only aberrant galactose-deficient IgA1 (Gd-IgA1).

Ticker(s): BHVN

Who's the expert?

Nephrologist
 

 

Interview Goal
This conversation will focus on the treatment landscape and potential use of BHV-1400 for patients with IgAN. 

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.